MN-SMITHS-MEDICAL
4.5.2021 14:02:10 CEST | Business Wire | Press release
Smiths Medical, a global medical device leader, today announced it has formed an exclusive partnership with Ivenix, Inc. that positions the companies as the first in the U.S. to offer a comprehensive suite of infusion management solutions to meet healthcare needs across the continuum of care. The long-term partnership, which includes a strategic investment from Smiths Medical, unites two innovators under a common goal of revolutionizing infusion management to improve patient safety and meet the needs of healthcare providers today and into the future.
Ivenix, a medical technology company dedicated to eliminating infusion-related patient harm, developed the first and only large-volume infusion pump from the ground up to meet the latest U.S. Food and Drug Administration infusion pump guidelines addressing recurring safety issues with pumps. Ensuring patient safety and clinical efficiency are critical components of successful life-saving infusion management. Today, infusion-related errors account for more than 50% of the 1.5 million adverse drug events reported annually to the FDA,1 and infusion-related adverse drug events cost the healthcare system more than $2 billion annually.2
Smiths Medical’s complementary portfolio of market-leading infusion systems CADD® -Solis and Medfusion® include syringe and ambulatory pumps that serve adult and neonatal critical care, operating rooms, and pain management in both the hospital and home. By adding the Ivenix Infusion System to its U.S. product portfolio, Smiths Medical will accelerate its offering into the large-volume infusion device segment, which is estimated to be over $2 billion.
“As a researcher focused on large volume IV smart pumps, I am well aware of the many safety and usability issues that exist with current products,” said Karen K. Giuliano, Ph.D., RN, FAAN, MBA, an Associate Professor and Co-director of the Nursing-Engineering Center for Innovation at the University of Massachusetts Amherst. “Innovation in IV smart pumps is long overdue, and I am happy to see new options for acute care clinicians to consider for the delivery of life-saving fluids and medications in this very important area of patient safety.”
“The long-term partnership between Smiths Medical and Ivenix will ensure that we are bringing the next generation of infusion management solutions to hospitals across the U.S. and fulfills our commitment to helping connect patients to life-saving therapies and insights to providers,” said JehanZeb Noor, Smiths Medical CEO. “Our investment in Ivenix will help spur the research and development needed to continue building on this critical resource and provide holistic solutions for hospitals and health systems.”
The Ivenix Infusion System includes a large-volume infusion pump with administration sets, infusion management tools and analytics to inform care and advance efficiency. The system received 510(k) clearance in 2019 and sets a new standard in infusion delivery by rethinking safety, simplicity, and interoperability. The system is centered around both the patient and clinician and designed to reduce infusion-related errors and drive down the total cost of ownership.
“This partnership allows us to accelerate the commercial reach of our infusion platform, and together provide a portfolio of leading-edge infusion solutions to deliver the highest standard of safe and integrated infusion care,” said Ivenix CEO Jorgen B. Hansen.
Smiths Medical will launch the Ivenix infusion System as part of its infusion portfolio in the summer of 2021.
About Smiths Medical
A leading innovator of specialized medical technologies for global markets, focusing on the medication delivery, vital care, and safety devices market segments. For more information, visit www.smiths-medical.com .
About Ivenix
Ivenix, Inc. is a medical technology company with a vision to eliminate infusion-related patient harm. The company was founded to develop innovative solutions that transform infusion delivery. Ivenix designed an infusion system from the ground up to streamline medication delivery and bring infusion technology into the digital age. The Ivenix Infusion System includes a large-volume infusion pump supported by a robust infusion management system designed to set new standards in simplicity, intelligence, and reliability. For more information, visit ivenix.com . The Ivenix Infusion System is cleared by the FDA.
References:
- FDA report, data on file
- ODPHP. Health Care Quality and Patient Safety: Adverse Drug Events. 2017
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005275/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Helps Customers Accelerate Adoption of Latest VMware Cloud Foundation Innovations2.9.2026 22:30:00 CEST | Press release
NetApp solutions validated to support VCF 9.1, giving mutual customers access to a modern private cloud with enterprise-grade data management, cyber resilience, and cost-efficient scaling NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, announced new capabilities in NetApp ONTAP® have been tested and validated to support VMware Cloud Foundation (VCF) 9.1, giving customers an optimized and secure data infrastructure foundation for their private and hybrid clouds. By combining the advanced capabilities of VCF 9.1 with cost-effective and enterprise data management with built-in security features from NetApp, including safeguarding data against ransomware attacks with rapid recovery, mutual customers can lower costs and accelerate the deployment of their AI software into production. VMware Cloud Foundation 9.1 provides enterprises with a unified private cloud platform for running both traditional and modern workloads. NetApp's solutions are tested and validated to suppo
Venture Global Announces Closing of $3,000,000,000 364-Day Senior Secured Revolving Credit Facility2.9.2026 22:30:00 CEST | Press release
Venture Global, Inc. (“Venture Global”) announced today that its subsidiary Venture Global LNG, Inc. (“VGLNG”) has entered into a new, $3,000,000,000 364-day revolving credit facility (the “Facility”). Venture Global expects to use the proceeds from borrowings under the Facility for general corporate purposes of VGLNG and its subsidiaries, including to fund certain project costs for the CP2 and Plaquemines bolt-on expansions prior to their respective FIDs. Bank of America, N.A. served as Coordinating Lead Arranger and Sole Bookrunner and will also serve as Administrative Agent. BBVA, Goldman Sachs, ING, J.P. Morgan, Mizuho, MUFG, NBC, RBC, Scotia, SMBC, U.S. Bank, and Wells Fargo served as Coordinating Lead Arrangers and Barclays, Santander, and Deutsche Bank served as Joint Lead Arrangers. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Vent
Invivoscribe Begins Commercial Shipments of PrepQuant™ Systems, Enabling High-Sensitivity Sample Preparation for MRD Testing2.9.2026 21:31:00 CEST | Press release
New automated platform is designed to improve the quality, efficiency, and consistency of DNA extraction and concentration from large-volume blood and plasma samples, supporting downstream assays capable of detecting disease-associated signals at MRD sensitivity levels. Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced that commercial shipments of the PrepQuant™ System have begun in North America. First unveiled at the American Association for Cancer Research Annual Meeting in April 2026, PrepQuant is now being delivered to customers, marking the platform's progression from development and validation into commercial deployment. The commercial milestone extends Invivoscribe's capabilities into laboratory instrumentation and addresses a critical bottleneck in highly sensitive molecular testing: efficiently recovering, concentrating, and quantifying DNA from larger blood and plasma inputs. PrepQuant is assay agnostic, de
C.H. Guenther Opens Centre of Excellence in Coventry, UK to Accelerate Bakery Innovation and Support Future Manufacturing Growth Across UK and Europe2.9.2026 18:00:00 CEST | Press release
C.H. Guenther & Son LLC (“C.H. Guenther” or “CHG”), a leading food manufacturer, has opened a new Centre of Excellence (the “Centre”) at its flagship Coventry bakery, creating a dedicated innovation and customer collaboration hub designed to accelerate the development of premium bakery products across the UK and Europe. The new facility has been designed to support CHG’s customers including leading global quick service restaurants, foodservice operators and retailers as they develop, test and refine new bakery products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902696890/en/ The purpose-built, 172-square-metre Centre of Excellence brings together a commercial-scale bakery, customer demonstration kitchen, sensory evaluation facilities, innovation suite and dedicated collaboration spaces in one specialized location. Designed to support and accelerate product development from concept through to commercial manufacturing,
Record Asset Management Enters New Phase of Growth2.9.2026 17:35:00 CEST | Press release
Record Asset Management GmbH (“RAM”), a subsidiary of London-listed Record plc (“Record” or the “Group”), is pleased to announce that it is now operating cashflow positive, thereby marking a transition from its investment phase into a growth business within the Group, and a significant milestone towards sustainable profitability. RAM is the European asset management arm of Record, the London-listed specialist investment group managing USD 122 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. RAM was established as a sister company to Record’s core currency business and obtained its BaFin license in 2022. RAM has grown rapidly in the last two years and has developed into a diversified private markets platform with dedicated infrastructure e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
